News

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Subcommittee Republicans, wrote to Department of Health and Human Services (HHS) Secretary Xavier Becerra.  The letter outlines concerns with the role HHS Office of Civil Rights (OCR) plays—or fails to play—in investigating instances of sexual harassment that occurs at research institutions which receive grants from the National Institutes of Health (NIH).  KEY EXCERPTS :  “There have been several public reports of sexual harassment occurring on NIH-funded research or NIH-supported activities over the last decade, and it raises concerns about what, if any, actions the NIH has taken to resolve these issues. The NIH’s own statistics show a significant problem with more than 300 cases related to sexual or gender harassment since 2018—with about a third of those allegations being substantiated. This also represents hundreds of men and women who may be forced to operate in a hostile or unsafe research environment.”  [...]  “According to the HHS website, OCR does investigate and resolve complaints of sexual harassment in the education and health programs of recipients of grants or other federal financial assistance from HHS—including the NIH. Moreover, HHS OCR is required to conduct periodic compliance reviews of institutional Title IX programs to ensure compliance with the law—including examining the way in which complaints are handled by the institution.”  The Chairs have requested answers to questions about HHS OCR’s role by April 30, 2024.  BACKGROUND :  Based on a recommendation from the U.S. Government Accountability Office (GAO), HHS OCR and the NIH adopted a memorandum of understanding (MOU) to facilitate communication between the two components of HHS as it relates to sexual harassment.   This MOU was intended to clarify procedures on how the enforcement arm of HHS and the grant-making arm share valuable information with one another in an effort to respond appropriately to complaints of sexual harassment and prevent federal grant money from going to those with a history of sexual misconduct.   TIMELINE OF INVESTIGATION :  August 10, 2021 : E&C Republican Leaders Question NIH’s Handling of Sexual Harassment Complaints  August 11, 2022 : E&C Republican Leaders follow up with NIH on Insufficient Response to its Letter on the NIH’s handling of Sexual Harassment  November 30, 2022 : E&C Republicans to NIH: Turn Over Previously Requested Information Ahead of New Congress  March 14, 2023 : E&C Republicans Press NIH for Information on Handling of Sexual Harassment Complaints  October 6, 2023 : E&C Republicans Signal Intent to Issue Subpoenas to Obtain Information on NIH’s Handling of Sexual Harassment if Questions Go Unanswered  January 26, 2024 : Chair Rogers notifies NIH of Imminent Subpoena  February 5, 2024 : Chair Rodgers Subpoenas NIH for Documents Related to Investigation into Sexual Harassment at NIH and NIH Grantee Institutions February 20, 2024: HHS Responds on behalf of NIH to offer a rolling in camera document review to the Committee. Documents produced in the review have been highly redacted, including the redaction of the names of individuals convicted of criminal offenses, public news articles about individuals who have been found guilty of harassment, and redaction of the names of the institutions where the abuse occurred—effectively preventing the Committee from understanding if NIH continues to fund work performed by substantiated abusers at other institutions—a practice known as “pass the harasser.”

Washington D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ), Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL) wrote to UnitedHealth Group, Inc., CEO Andrew Witty today seeking information about the cyberattack on Change Healthcare. Change Healthcare, which was acquired by UnitedHealth Group’s Optum subsidiary in 2022, is one of the nation’s largest providers of health care payment management systems. On February 21, UnitedHealth Group reported it had experienced a cyberattack on its platforms, and it had taken all Change Healthcare systems offline to contain the incident. As a result of the outage, critical services affecting patient care—including billing services, claims transmittals, and eligibility verifications—became inoperable. Though UnitedHealth first notified users that it expected the disruption to “last at least through the day,” several of the company’s products have now been inoperable for more than a month. “Change Healthcare is a central player in the country’s health care system, which has been upended by the recent breach,” t he bipartisan Committee leaders wrote to Mr. Witty. “We are interested in your efforts to secure Change Healthcare’s systems since it was acquired by your company and the efforts you are taking to restore system functionality and support patients and providers affected by the attack.” Change Healthcare’s platforms touch an estimated one in three U.S. patient records. Its systems process roughly 15 billion transactions annually, and are linked to approximately 900,000 physicians, 118,000 dentists, 33,000 pharmacies, and 5,500 hospitals nationwide. The breadth of Change Healthcare’s infrastructure all but ensures that the scope of the current disruption, and any disruption in Change Healthcare services, will be extensive. “The health care system is rapidly consolidating at virtually every level, creating fewer redundancies and more vulnerability to the entire system if an entity with significant market share at any level of the system is compromised,” the Committee leaders wrote. “In order to understand better the steps UnitedHealth has taken to address this situation, we request information about the impact of the cyberattack, the actions the company is taking to secure its systems, and the outreach to the health care community in the aftermath.” As a result of the system outage, providers reportedly struggled to make payroll while some patients have been forced to pay out of pocket for crucial medications including cancer therapy drugs and insulin because pharmacies are unable to verify coverage. The Committee leaders requested answers to a series of detailed questions by April 29, 2024. CLICK HERE to read the full letter. 

Washington, D.C. — House Energy and Commerce Committee (E&C) Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), and E&C Subcommittee on Health Chair Brett Guthrie (R-KY), Select Subcommittee on the Coronavirus Pandemic Chair Brad Wenstrup (R-OH), and House Oversight and Accountability Committee Chair James Comer (R-KY) announced that EcoHealth Alliance (EcoHealth) President Dr. Peter Daszak will appear for a public hearing on May 1, 2024. EcoHealth—a U.S.-based non-profit whose mission is to prevent pandemics—used taxpayer dollars to fund dangerous gain-of-function research at the Wuhan Institute of Virology (WIV). During his closed-door transcribed interview with the Committees on November 14, 2023, Dr. Daszak made multiple statements inconsistent with documents and evidence reviewed by the Committees. This raises serious questions about the veracity of EcoHealth’s public statements, including its insistence that the research it funded at the WIV could not have caused the pandemic. The Chairs are calling on Dr. Daszak to address the discrepancies in his testimony and publicly explain EcoHealth’s relationship with the WIV. “These revelations undermine your credibility as well as every factual assertion you made during your transcribed interview. The Committees have a right and an obligation to protect the integrity of their investigations, including the accuracy of testimony during a transcribed interview. We invite you to correct the record,” wrote the Chairs. In preparation for the public hearing next month, the Chairs are also requesting further information from Dr. Daszak about EcoHealth’s communication with the WIV, public health agencies, and prominent individuals involved in the suppression of the lab-leak hypothesis. BACKGROUND: Dr. Daszak told the Committees that EcoHealth intended to conduct dangerous gain-of-function research on bat coronaviruses at a University of North Carolina lab if its proposal—known widely as DEFUSE—was approved by the Defense Advanced Research Projects Agency (DARPA). A recently released Freedom of Information Act document production directly contradicts this statement and suggests that EcoHealth intended to mislead DARPA and conduct the risky research at the WIV instead. Dr. Daszak’s statements require correction and clarification as these documents suggest that EcoHealth intended to conduct research at laboratories with weaker biosafety measures set by the Chinese government instead of at laboratories with higher biosafety standards required by the United States.  Scientific evidence and available intelligence indicate that a research-related incident at a lab in Wuhan remains a plausible cause of the COVID-19 pandemic. EcoHealth’s negligent, haphazard approach to biosafety and grant compliance, coupled with the misleading statements by Dr. Daszak to the Committees, raises serious concerns that must be further addressed at the hearing. CLICK HERE to read the Committees letter to Dr. Daszak.

Washington, D.C. — In a new letter, House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), on behalf of the Health and Oversight Republicans, wrote to Government Accountability Office Comptroller General Gene Dodaro. KEY QUOTE :  “We write to request that the Government Accountability Office (GAO) examine the extent to which the National Institutes of Health (NIH) adequately safeguards research funds from national security concerns related to the Chinese military or over the unethical use of human beings in research studies, especially from entities of concern in China.”   The Chairs have particular concerns about NIH funding that is tied to:  Researchers with affiliations with the “Seven Sons of National Defense,” a group of seven universities with historical ties with China’s military defense industry.  Questionable Chinese research entities, including BGI—a firm based in Shenzhen picked by the Chinese government to build and operate the China National GeneBank.  The unethical use of Chinese ethnic minority data in research studies, including that from Tibetan or Uyghur populations.  BACKGROUND :  Recent reports have raised concerns about the NIH’s ability to screen for national security issues.   A six-month investigation by Vanity Fair found that for a decade, warnings were issued by the Department of Energy to the NIH concerning the risk that U.S.-funded biology research could be misused by overseas partners.   Recent reports from the U.S. Department of Health and Human Services Office of the Inspector General and GAO have noted NIH safeguarding problems regarding foreign grant recipients.   Recently, a student from China who was headed to the National Cancer Institute was repatriated at Dulles Airport after interrogation from Department of Homeland Security officials about ties to the Chinese government, Chinese military, or state laboratories.  Concerns about the NIH’s ability to vet foreign collaborators have also arisen from the Committee’s investigation of the origins of the COVID-19 pandemic.  CLICK HERE to read the full letter.

Washington, D.C. — This past January, House Energy and Commerce Committee Republicans revealed the earliest known SARS-CoV-2 sequence released outside of China, calling in to question China’s transparency . In a new letter , Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) have requested National Institutes of Health (NIH) Director Monica Bertagnolli provide the files of all SARS-CoV-2 submissions to GenBank prior to January 10, 2020. Any such data would better inform the Committee’s ongoing investigation into the origins of COVID-19. KEY LETTER EXCERPT :  “We were dismayed to learn that the NIH had received eight pages of genetic code and a nearly complete version of the genetic sequence for SARS-CoV-2, almost two weeks before the sequence was made public. However, the NIH apparently had no situational awareness in early January 2020 about this genetic code while high-level officials in our government were attempting to get the sequence, including directly from the Chinese government.  “The circumstances suggest the possibility that there may be other early versions of the SARS CoV-2 sequence that were submitted to the National Center for Biotechnology Information (NCBI’s) Genbank but were not posted. Since such potential submissions could provide clues about the timing of the pandemic and how SARS CoV-2 was evolving at the beginning of the pandemic, there is a strong public interest to conduct further due diligence to check GenBank for such submissions.”  BACKGROUND :  January 17, 2024 : E&C Investigation Uncovers Earliest Known SARS-CoV-2 Sequence Released Outside of China  September 28, 2023 : E&C Republicans Signal Intent to Issue Subpoenas as Biden Admin Stonewalls Crucial Investigations into Government Health Agency Actions  August 9, 2023 : E&C Presses Unresponsive NIH for Answers about COVID Origins and Risky Research Projects  May 3, 2023 : E&C Republicans Seek Data and Documents from NIH on Early COVID Cases

Committee seeks to save lives and ensure proper implementation of new bipartisan law Washington, D.C. — Bipartisan leaders of the Energy and Commerce Committee launched an investigation into United Network for Organ Sharing (UNOS), the sole contractor responsible for operating the Organ Procurement and Transplantation Network (OPTN). The Leaders are also seeking information from the Health Resources and Services Administration (HRSA) regarding ongoing reforms. The effort seeks to examine issues with OPTN’s prior operation and ensure proper implementation of the bipartisan Securing the U.S. Procurement and Transplantation Network Act , which was passed unanimously by the Committee and by Congress and signed into law by President Biden on September 22, 2023. The inquiry is led by Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr. (D-NJ); Subcommittee on Health Chair Brett Guthrie (R-KY) and Ranking Member Anna G. Eshoo (D-CA); and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) and Ranking Member Kathy Castor (D-FL). The Committee Leaders wrote to HRSA requesting information on how its OPTN contract solicitation plan will support fair and competitive practices during the contracting process, promote data transparency and patient safety, and ensure system security and operability. KEY LETTER EXCERPT: “ Errors and inefficiencies in OPTN management can have deadly consequences . A HRSA-funded study found that, while Americans die each day waiting for organ transplants, as few as one in five potential donor organs have been recovered. The Committee wants to ensure HRSA’s ability to manage the successful implementation of the OPTN Modernization Initiative to improve accountability and effectiveness of the system that does not currently meet the needs of patients .” The Committee leaders also sent questions to UNOS Chief Executive Officer Maureen McBride regarding UNOS’s system security and operability, issues with patient safety and equity, and conflict-of-interest concerns. KEY LETTER EXCERPT : “A 2021 report, by the United States Digital Service titled 'Lives Are at Stake' found myriad problems with UNOS technology, concluding that ‘[t]he OPTN contractor lacks sufficient technical capabilities to modernize their systems,’ ‘[t]he core systems are fragile,’ and the system uptime is ‘insufficient’ for a life-saving system that depends on consistent operation. “An August 2022 report from the Department of Health and Human Services (HHS) OIG found multiple, basic cybersecurity failures by UNOS. The OIG report noted that UNOS’s policies and procedures for access controls, risk assessment, and system monitoring ‘were either in draft or did not exist.’ Given the highly sensitive nature of the personal patient data UNOS keeps, it is vital that strong and enforceable security measures are required and consistently met under any OPTN management contracts. “ UNOS has been the sole organization managing the OPTN, during which time concerning reports have emerged that the organ donation system has become unsafe , inequitable , self-dealing , and retaliatory . The Committee supports HRSA’s proposed reforms to make the contracting process truly competitive to help ensure patients are served by the best contractors for each function.” BACKGROUND : The OPTN is a unique public-private partnership that links all professionals involved in the U.S. donation and transplantation system.  Since its inception, the OPTN contract has only been awarded to a single contractor—UNOS.  To address concerns with the donation and transplantation system, Congress passed legislation led by Rep. Larry Bucshon (R-IN) and Rep. Robin Kelly (D-IL), which was signed into law in 2023, to modernize OPTN and allow HRSA to run a competitive process to choose the best contractors for different national OPTN functions.  Additionally, HRSA has also announced a Modernization Initiative to improve accountability and effectiveness of the system in order to better meet the needs of patients.  Alarm over ignored patient safety concerns suggests that both HRSA and UNOS systematically downplayed or ignored critical patient safety concerns, risking lives and undermining trust in the national organ transplantation system.

Washington D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) wrote to U.S. Government Accountability Office (GAO) Comptroller General Gene Dodaro. In their letter , the Chairs request GAO examine how the Substance Abuse and Mental Health Services Administration (SAMHSA) has administered about $8 billion in COVID-19 supplemental funding, as well as nearly $1 billion in new funds provided to launch the 9-8-8 Suicide and Crisis Lifeline (9-8-8 Program).  Following previous inquires by the Committee, SAMHSA finally released data that shows states and grantees have failed to use even half of all these funds.  BACKGROUND :  According to SAMHSA’s budget overview, SAMHSA’s annual budget authority for fiscal year 2021 was $5.8 billion, but it also received more than $7.8 billion in additional money through the COVID-19 supplemental funding.   Like other federal and state government agencies, SAMHSA quickly had to manage priorities and oversee this influx of money to address challenges posed by the COVID-19 pandemic.  Last year, in three separate letters, the Chairs requested that SAMHSA provide a full accounting for how the influx of funding had been spent.  SAMHSA’s response showed that it had obligated most of this funding—$8.2 billion in COVID-19 supplemental funding and over $850 million for the 9-8-8 Program as of November 2023—primarily through grants to states and other grantees.   However, SAMHSA grantees only spent about $4 billion out of the nearly $8 billion in COVID-19 supplemental funding and only about $350 million for the 9-8-8 program.  KEY LETTER EXCERPT :  “SAMHSA’s response also shows that the states and other grantees had used less than half of these obligated amounts by that date. In light of this, we have concerns about the nature and pace of using these funds, as well as SAMHSA’s ability to administer and oversee this additional funding.”  The Chairs request GAO provide a report that addresses the following questions:  To what extent have states and other grantees used SAMHSA’s COVID-19 supplemental funding allocated to grants, and funding for the 9-8-8 Program?  What information does SAMHSA collect on how states and other grantees have used this grant funding?  What factors have affected states’ and other grantees’ ability to use these funds?  What information is available on how states and other grantees will use any remaining funds?  How has this additional grant funding affected SAMHSA’s administration and oversight, and what adjustments, if any, has SAMHSA made to accommodate the influx?  CLICK HERE to read the full letter. 

Washington, D.C. — After public reports of a large-scale, year-long Medicare fraud scheme involving catheter billing, leaders from the Energy and Commerce, Ways and Means, and Oversight and Accountability committees, along with GOP Doctors Caucus Co-Chairs, are seeking a briefing from Department of Health and Human Services (HHS) Inspector General (IG) Christi Grimm and Centers for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure. In a new letter, the lawmakers request briefings from the HHS IG and CMS by March 20, 2024, regarding what steps are being taken to address this reported fraud and prevent its reoccurrence.  KEY LETTER EXCERPTS : “It is imperative that the U.S. Department of Health and Human Services Office of the Inspector General take immediate action to reduce improper payments and ensure that taxpayer dollars are directed towards the care of our senior citizens whom Medicare is intended to serve. “Based on the information that is publicly known to date, the scale of the alleged catheter billing fraud, affecting over 450,000 Medicare beneficiaries, may represent a significant failure by CMS and HHS OIG. This dramatic, multifold increase in catheter billing—from just a handful of companies—should have been quickly identified and addressed. If public reports about the apparent ease with which this fraud was perpetrated are accurate, they raise questions about the efficacy of current CMS and the HHS OIG fraud detection and prevention measures. In addition, there are stakeholder concerns that a similar increase in fraud has occurred in diabetes supplies, and that this increase may be evidence of a new fraud against the Medicare program.” BACKGROUND : Public reporting estimates the cost of fraud from this scheme to be at least $2 billion. However, discussions between committee staff and stakeholders suggest the dollar figure may be closer to $3 billion. During the Trump administration, Medicare improper payments were reduced by billions per year. In the years since President Biden took office in January 2021, however, improper payments have increased dramatically. House Republicans have long raised the alarm about the prevalence of improper and fraudulent payments in the Medicare and Medicaid programs. In 2016, Republican Members of Congress wrote to then Centers for Medicare and Medicaid Services (“CMS”) Acting Administrator Andy Slavitt to express concern over the rise in Medicare's improper payments. Under the Biden administration, Medicare improper payments have an estimated total of $87.72 billion. Members signing the letter include: Energy and Commerce: Full Committee Chair Cathy McMorris Rodgers (R-WA) Health Subcommittee Chair Brett Guthrie (R-KY) Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA) Ways and Means Committee: Full Committee Chair Jason Smith (R-MO) Health Subcommittee Chair Vern Buchanan (R-FL) Oversight Subcommittee Chair David Schweikert (R-AZ) Oversight and Accountability Committee: Full Committee Chair James Comer (R-KY) Health Care and Financial Services Subcommittee Chair Lisa McClain (R-MI) GOP Doctors Caucus Co-Chair Greg Murphy, M.D. (R-NC) Co-Chair Michael Burgess, M.D. (R-TX) Co-Chair Brad Wenstrup, D.P.M. (R-OH) CLICK HERE to read the full letter.

Washington, D.C. — As part of its ongoing investigation into the origins of the COVID-19 pandemic and the adequacy of the National Institutes of Health’s (NIH) oversight of risky virus research, House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) have requested former senior NIH official Dr. Teresa Hauguel participate in a transcribed interview before the Committee.  KEY EXCERPT :  “As a former program officer at the National Institute of Allergy and Infectious Diseases (NIAID), documents indicate that you participated in internal institute committee meetings to determine whether certain virus research experiments presented risks that required additional scrutiny and possible actions to mitigate the risks such as redesign of the experiment. You have been identified by a senior official at NIAID as a subject matter expert for reviewing risks in respiratory virus research projects. For these reasons, we believe you could be helpful to the committee’s examination of virus research oversight, and thus, we request that you appear for a transcribed interview to be held on the week of March 4, 2024.”  CLICK HERE to read the letter.